Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1.
doi: 10.1111/iju.70253. Online ahead of print.

Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer

Yosuke Yasuda  1 , Soichiro Yoshida  1 , Daigoro Matsubara  2 , Taro Takahara  3 , Ryoichi Yoshimura  2 , Yasuhisa Fujii  1
Affiliations

Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer

Yosuke Yasuda et al. Int J Urol. .
No abstract available

Keywords: oligometastatic castration‐resistant prostate cancer; progressive site‐directed therapy; whole‐body diffusion‐weighted imaging.

PubMed Disclaimer

References

    1. P. Ost, D. Reynders, K. Decaestecker, et al., “Surveillance or Metastasis‐Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36 (2018): 446–453.
    1. S. Hellman and R. R. Weichselbaum, “Oligometastases,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 13 (1995): 8–10.
    1. S. Yoshida, T. Takahara, Y. Arita, et al., “Progressive Site‐Directed Therapy for Castration‐Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor,” International Journal of Radiation Oncology, Biology, Physics 105 (2019): 376–381.
    1. G. Francolini, A. G. Allegra, B. Detti, et al., “Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate‐Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO),” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 5561–5568.
    1. K. Decaestecker, G. de Meerleer, B. Lambert, et al., “Repeated Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence,” Radiation Oncology (London, England) 9 (2014): 135.

LinkOut - more resources